Brown Advisory Inc. grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 182,958 shares of the medical research company’s stock after buying an additional 815 shares during the period. Brown Advisory Inc.’s holdings in Amgen were worth $31,817,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Lingohr & Partner Asset Management GmbH boosted its position in shares of Amgen by 71.4% during the second quarter. Lingohr & Partner Asset Management GmbH now owns 8,165 shares of the medical research company’s stock valued at $1,340,000 after purchasing an additional 3,400 shares in the last quarter. Thrivent Financial For Lutherans boosted its position in shares of Amgen by 107.1% during the second quarter. Thrivent Financial For Lutherans now owns 118,342 shares of the medical research company’s stock valued at $20,382,000 after purchasing an additional 61,212 shares in the last quarter. Verity Asset Management Inc. boosted its position in shares of Amgen by 363.8% during the second quarter. Verity Asset Management Inc. now owns 8,989 shares of the medical research company’s stock valued at $1,548,000 after purchasing an additional 7,051 shares in the last quarter. Investec Asset Management LTD boosted its position in shares of Amgen by 1,081.7% during the second quarter. Investec Asset Management LTD now owns 21,967 shares of the medical research company’s stock valued at $3,783,000 after purchasing an additional 20,108 shares in the last quarter. Finally, Fort L.P. bought a new stake in shares of Amgen during the second quarter valued at approximately $4,294,000. 79.53% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $189.75, for a total value of $289,368.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 4,575 shares of company stock valued at $838,064 in the last 90 days. Company insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. During the same period last year, the firm posted $2.89 earnings per share. The company’s revenue was down 2.7% compared to the same quarter last year. research analysts predict that Amgen, Inc. will post 13.25 EPS for the current year.
Amgen declared that its board has authorized a stock buyback program on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 3.14%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio is currently 41.97%.
Several equities research analysts recently weighed in on AMGN shares. Oppenheimer set a $205.00 price target on Amgen and gave the company a “buy” rating in a research report on Tuesday, December 12th. Goldman Sachs lowered Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Citigroup lowered Amgen to a “neutral” rating in a research report on Monday, December 18th. Mizuho set a $192.00 price target on Amgen and gave the company a “buy” rating in a research report on Friday, December 22nd. Finally, Piper Jaffray restated a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company. Amgen currently has an average rating of “Hold” and an average price target of $190.57.
TRADEMARK VIOLATION WARNING: This story was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3342526/amgen-inc-amgn-shares-bought-by-brown-advisory-inc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.